ClinicalTrials.gg
Active, not recruitingNCT03337919ANIMATEUpdated May 10, 2024

ANIMATE: Phase II Study of Nivolumab Monotherapy for Relapsed/Refractory Hodgkin Lymphoma

A Phase 2 interventional study of Nivolumab in Hodgkin Lymphoma, sponsored by University College, London. Active, not recruiting at 10 sites in United Kingdom. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2024-05-10.

Sponsored by University College, London · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
78
Allocation
Not applicable
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 52 studies testing nivolumab in Hodgkin Disease — 17 open to participants now, 32 under way, 4 of them phase 3. Nivolumab · Hodgkin Disease.

Enrollment
19th of 52
78 · median 52
Started
2018
with 6 others
Phase 2
33 of 52
12 open now
Primary completion
2023-03
later than 3 of 31 live
Registered
17th of 52
by date

Among the 52 studies testing nivolumab in Hodgkin Disease, this one is the 19th largest by enrollment, is one of 7 that started in 2018, is one of 33 in phase 2, reaches primary completion later than 3 of the 31 other live ones, and was the 17th registered.

Hodgkin Disease

1,384 studies on the registry are indexed under Hodgkin Disease; 163 are open to participants now.

Browse Hodgkin Disease studies →

Open to participants now

17 of the 52 studies testing nivolumab in Hodgkin Disease are open now, in 11 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 136 Hodgkin Disease studies recruiting now, 73 (54%) set no upper age limit and 51 (38%) stop at 75 or younger; 46 take children under 18; 10 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies testing nivolumab in Hodgkin Disease, or all of them as a file.
02

Study summary

This is a single-arm, phase II, multi-centre study of the safety and efficacy of the PD-1 inhibitor, nivolumab, as second-line or third-line salvage therapy as a bridge to stem cell transplant (SCT) in relapsed/ refractory classical Hodgkin lymphoma patients not achieving a complete metabolic response (CMR) on FDG-PET-CT scan after first or second line salvage therapy.

Read the detailed description

This is a single-arm, phase II, multi-centre study of the safety and efficacy of the programmed cell death protein 1 (PD-1) inhibitor, nivolumab, as second-line or third-line salvage therapy, and in particular as a bridge to stem cell transplant (SCT) in relapsed/ refractory classical Hodgkin lymphoma patients not achieving a complete metabolic response (CMR) on fluorodeoxyglucose positron emission tomography (FDG-PET) scan post first or second line salvage therapy.

Approximately 120 patients with relapsed/refractory classical Hodgkin lymphoma will be registered while undergoing first or second line salvage therapy (first line is preferred).

Patients will have a centrally reviewed PET CT scan after first or second line salvage therapy. Those with complete metabolic response (CMR) on PET CT scan (Deauville score 1-3) will not be eligible for trial treatment. They will be followed up for trial data collection purposes, and further management will be at their treating clinician's discretion.

Patients achieving less than CMR on central review of FDG-PET (Deauville score 4-5) will be eligible to receive up to 8 x 2-weekly nivolumab infusions. 30 patients will be treated on the trial.

After 4 courses of nivolumab, patients will have an additional centrally reviewed PET-CT scan (PET4). Patients achieving CMR will stop trial treatment, and enter follow up. Further treatment will be at their clinician's discretion but is likely to be stem cell transplant (SCT). Patients with partial metabolic response (PMR) or stable disease (SD) on PET4 will receive a further 4 cycles of nivolumab, again followed by a centrally reviewed PET-CT scan (PET8) to assess final response.

Further management after PET8 will be at the discretion of the treating clinician, although it is anticipated that those with CMR or PMR will proceed to SCT. If PET8 shows less than CMR (i.e. PMR or SD), patients who consent will have a further biopsy to exclude false positive PET signal; this will be centrally reviewed.

Patients with progressive metabolic disease (PMD) on nivolumab at any point will stop trial treatment. If a repeat biopsy is obtained to confirm progressive disease histologically, the biopsy material will be centrally reviewed.

Patients will be followed up for a minimum of 3 years.

03

Conditions studied

  • Hodgkin Lymphoma

Browse trials for

Keywords

  • Nivolumab
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion criteria for study registration:

  1. Age 16 or over
  2. Primary classical Hodgkin lymphoma or classical Hodgkin lymphoma in first relapse
  3. About to receive or receiving first or salvage therapy (up to a maximum of 14 days after last treatment)
  4. Fit for stem cell transplantation
  5. Written
  6. Willing to comply with the requirements of the trial

Exclusion criteria for study registration:

  1. Nodular lymphocyte predominant Hodgkin lymphoma
  2. Women who are pregnant or breastfeeding
  3. History of colitis, inflammatory bowel disease or pneumonitis
  4. Patients with disorders, except patients with vitiligo, diabetes mellitus type 1, hypo- and hyperthyroidism not requiring therapy
  5. Known history of or C infection
  6. Known infection
  7. History of allergy (including severe/life threatening skin reaction) to monoclonal antibodies, anaphylaxis or uncontrolled allergy
  8. Major surgery within 4 weeks prior to registration
  9. Myocardial infarction, unstable angina, coronary artery bypass graft, cerebrovascular accident or within the past 6 months
  10. Non-haematological within the past 3 years (with some exceptions - listed in protocol)

Inclusion criteria for trial treatment:

  1. Has received 2 cycles of first or second line salvage chemotherapy
  2. PET positive (Deauville score 4 or 5) after first or second line salvage chemotherapy
  3. Fit for further salvage chemotherapy
  4. performance status 0-1
  5. >30ml/min calculated by Cockcroft-Gault formula
  6. \<1.5 x , /AST \<2.5 x ULN
  7. Adequate bone marrow function ( >80g/l, >50 x 10\^9/l, neutrophils >1.0 x 10\^9/l)

Exclusion criteria for trial treatment:

  1. Deauville score 1-3 after first or second line salvage chemotherapy
  2. Positive serology for hepatitis B or C (some exclusions apply - see protocol)
  3. Active infection requiring systemic therapy
  4. Ongoing requirement for immunosuppressive therapy, apart from inhaled, intranasal, topical or systemic corticosteroids at low doses (≤10mg prednisolone per day, or the equivalent)
  5. Corticosteroids at a dose of more than 10mg per day prednisolone or equivalent within 7 days prior to response PET-CT. NOTE: corticosteroids can be used AFTER a positive PET-CT scan for symptomatic disease but must be weaned to a dose of prednisolone ≤10mg/day or less (or equivalent) at least 7 days prior to starting nivolumab.
  6. Treatment with any agent within 28 days prior to planned start of nivolumab
  7. Ongoing grade 2-4 non-haematological toxicities related to prior Hodgkin lymphoma treatments, with the exception of alopecia and grade 2 fatigue
  8. Pregnant or breastfeeding women
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
78 participants (actual)

Study arms

  • Experimental
    Nivolumab

    Up to 8 x 2-weekly cycles of nivolumab 240mg IV. Interim PET-CT scan to be performed after 4 cycles, and centrally reviewed. Patients will stop treatment after 4 cycles if they have complete metabolic response or progressive metabolic disease. If they have partial metabolic response or stable disease, they will continue to 8 cycles.

    Drug: Nivolumab

Interventions

  • Up to 8 cycles of nivolumab

    Also known as: Opdivo®

06

What researchers measure

Primary outcomes

  1. Overall response rate (ORR) by PET-CT scan following 4-8 cycles of nivolumab

    Rate of patients achieving complete metabolic response (CMR) on PET-CT scan following 4 or 8 cycles of nivolumab

    Time frame: 4 months

Secondary outcomes

  1. Progression-free survival

    Progression-free survival at 1 year; also to be analysed stratified by partial metabolic response vs complete metabolic response.

    Time frame: 1 year

  2. Overall survival

    Overall survival at 1 year; also to be analysed stratified by partial metabolic response (PMR) vs complete metabolic response (CMR).

    Time frame: 1 year

  3. Proportion of patients progressing to stem cell transplant

    Proportion of patients progressing to autologous or allogeneic stem cell transplant

    Time frame: 1 year

  4. Adverse events [Safety and toxicity of nivolumab]

    Adverse events and serious adverse events occurring in patients treated with nivolumab, in particular autoimmune toxicity

    Time frame: 3 years

  5. Transplant-related mortality

    Proportion of patients treated with nivolumab that subsequently die of transplant-related causes

    Time frame: 3 years

  6. Transplant-related morbidity

    Proportion of patients treated with nivolumab that go on to suffer serious complications of allogeneic transplant (grade 3-4 graft-versus-host disease, hyperacute graft-versus-host disease and steroid-responsive febrile syndrome)

    Time frame: 3 years

Other outcomes

  1. Biopsy-negative PMR rate

    Correlation of PET positive disease with histological evidence of disease on post-treatment repeat biopsy to establish biopsy negative PMR rate (subject to patient consent)

    Time frame: 4 months

  2. Serological biomarkers of response to nivolumab

    Correlation of disease response with serological markers such as serum Thymus and activation-regulated chemokine (TARC) levels

    Time frame: 5 months

  3. Immunological biomarkers of response to treatment

    Evaluate the correlation between response to nivolumab and biological parameters e.g. PD-L1 expression on Reed Sternberg cells

    Time frame: 4 months

07

Study locations

10 sites
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2018 to primary completion in Mar 2023, 50 months.

Of 182 non-industry phase 2 interventional studies under Hodgkin Disease, half reached primary completion within 80 months of starting (the median), counting those still running; a quarter within 48 and three quarters within 115. This study's 50 months is below that.

Counting every sponsor, half of 205 studies reached it within 75 months; a quarter within 42 and three quarters within 111.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2017
First posted
Nov 9, 2017
StartActual
Dec 3, 2018
Primary completionActual
Mar 1, 2023
CompletionEst.
Feb 28, 2026
Last update
May 10, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 10, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03337919
Responsible party
Sponsor
First posted
Nov 9, 2017
Start date
Dec 3, 2018
Primary completion
Mar 1, 2023
Completion
Feb 28, 2026 (estimated)
Last update
May 10, 2024

Study contacts

Graham Collins
principal investigator · Oxford University Hospitals NHS Trust

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nivolumab

Start the discussion